GSK to Approach FDA With Positive Phase III Data For Long-Acting Asthma Med

GSK’s twice-yearly depemokimab reduced asthma attacks by half and cut clinic visits by nearly three-quarters, positioning it for an estimated $4 billion in peak sales if approved.